Bioline RX Ltd Company Profile (NASDAQ:BLRX)

About Bioline RX Ltd (NASDAQ:BLRX)

Bioline RX Ltd logoBioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BLRX
  • CUSIP: N/A
  • Web: www.biolinerx.com
Capitalization:
  • Market Cap: $49.71 million
  • Outstanding Shares: 58,620,000
Average Prices:
  • 50 Day Moving Avg: $0.86
  • 200 Day Moving Avg: $1.00
  • 52 Week Range: $0.71 - $1.42
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 14.13
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.61 per share
  • Price / Book: 1.39
Profitability:
  • EBIDTA: ($17,590,000.00)
  • Return on Equity: -36.69%
  • Return on Assets: -34.08%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 11.73%
  • Quick Ratio: 11.73%
Misc:
  • Average Volume: 503,805 shs.
  • Beta: 0.58
  • Short Ratio: 0.37
 

Frequently Asked Questions for Bioline RX Ltd (NASDAQ:BLRX)

What is Bioline RX Ltd's stock symbol?

Bioline RX Ltd trades on the NASDAQ under the ticker symbol "BLRX."

How were Bioline RX Ltd's earnings last quarter?

Bioline RX Ltd (NASDAQ:BLRX) announced its quarterly earnings results on Thursday, May, 25th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.03. View Bioline RX Ltd's Earnings History.

Where is Bioline RX Ltd's stock going? Where will Bioline RX Ltd's stock price be in 2017?

4 equities research analysts have issued 1 year price targets for Bioline RX Ltd's stock. Their forecasts range from $1.10 to $7.00. On average, they anticipate Bioline RX Ltd's stock price to reach $3.62 in the next twelve months. View Analyst Ratings for Bioline RX Ltd.

What are analysts saying about Bioline RX Ltd stock?

Here are some recent quotes from research analysts about Bioline RX Ltd stock:

  • 1. According to Zacks Investment Research, "Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. " (5/26/2017)
  • 2. Maxim Group analysts commented, "BioLineRx announced a collaboration with Genentech (Roche) to evaluate BL-8040 in combination with Genentech’s checkpoint inhibitor atezolizumab (PD-L1) in multiple solid tumors, as well as in AML (acute myeloid leukemia)." (9/7/2016)

Who are some of Bioline RX Ltd's key competitors?

Who owns Bioline RX Ltd stock?

Bioline RX Ltd's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BIOTECHNOLOGY VALUE FUND L P (18.30%), Sabby Management LLC (5.09%), Morgan Stanley (1.24%), KCG Holdings Inc. (0.28%), Benchmark Capital Advisors (0.23%) and Renaissance Technologies LLC (0.21%). View Institutional Ownership Trends for Bioline RX Ltd.

Who bought Bioline RX Ltd stock? Who is buying Bioline RX Ltd stock?

Bioline RX Ltd's stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC, KCG Holdings Inc., Morgan Stanley, Renaissance Technologies LLC, Benchmark Capital Advisors and Citadel Advisors LLC. View Insider Buying and Selling for Bioline RX Ltd.

How do I buy Bioline RX Ltd stock?

Shares of Bioline RX Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bioline RX Ltd stock cost?

One share of Bioline RX Ltd stock can currently be purchased for approximately $0.85.

Analyst Ratings

Consensus Ratings for Bioline RX Ltd (NASDAQ:BLRX) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.62 (326.89% upside)

Analysts' Ratings History for Bioline RX Ltd (NASDAQ:BLRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/27/2017HC WainwrightSet Price TargetBuy$4.00N/AView Rating Details
5/25/2017Maxim GroupSet Price TargetBuy$3.00LowView Rating Details
2/13/2017Rodman & RenshawInitiated CoverageBuy$3.00N/AView Rating Details
11/28/2016Roth CapitalReiterated RatingBuy$7.00N/AView Rating Details
9/23/2016S&P Equity ResearchLower Price Target$1.24 -> $1.10N/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$3.50 -> $3.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$3.50 -> $3.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Bioline RX Ltd (NASDAQ:BLRX)
Earnings by Quarter for Bioline RX Ltd (NASDAQ:BLRX)
Earnings History by Quarter for Bioline RX Ltd (NASDAQ:BLRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/25/20173/31/2017($0.05)($0.08)$0.01 millionViewN/AView Earnings Details
3/23/201712/31/2016($0.08)($0.13)$0.02 millionViewN/AView Earnings Details
11/22/2016Q316($0.07)($0.08)ViewN/AView Earnings Details
8/11/2016Q216($0.07)($0.07)ViewListenView Earnings Details
5/17/2016Q116($0.08)($0.10)ViewListenView Earnings Details
3/10/2016Q415($0.06)($0.07)ViewListenView Earnings Details
11/16/2015Q315($0.08)($0.03)ViewListenView Earnings Details
8/20/2015Q215($0.10)($0.09)ViewListenView Earnings Details
5/18/2015Q115($0.10)($0.08)ViewListenView Earnings Details
11/10/2014Q314($0.11)($0.02)ViewN/AView Earnings Details
8/6/2014Q214($0.09)($0.12)ViewN/AView Earnings Details
5/20/2014Q114($0.11)($0.01)ViewN/AView Earnings Details
3/17/2014($0.15)($0.20)ViewN/AView Earnings Details
11/13/2013($0.18)($0.20)ViewN/AView Earnings Details
8/6/2013Q213($0.02)ViewN/AView Earnings Details
5/7/2013($0.02)($0.20)ViewN/AView Earnings Details
11/14/2012Q312($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bioline RX Ltd (NASDAQ:BLRX)
Current Year EPS Consensus Estimate: $-0.230 EPS
Next Year EPS Consensus Estimate: $0.060 EPS

Dividends

Dividend History for Bioline RX Ltd (NASDAQ:BLRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bioline RX Ltd (NASDAQ:BLRX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Bioline RX Ltd (NASDAQ:BLRX)
Latest Headlines for Bioline RX Ltd (NASDAQ:BLRX)
Source:
DateHeadline
americanbankingnews.com logoBioline RX Ltd (BLRX) Given a $4.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 27 at 9:34 AM
americanbankingnews.com logoBioline RX Ltd (BLRX) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 26 at 7:14 PM
americanbankingnews.com logoBioline RX Ltd (BLRX) Posts Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 26 at 8:24 AM
americanbankingnews.com logoMaxim Group Analysts Give Bioline RX Ltd (BLRX) a $3.00 Price Target
www.americanbankingnews.com - May 25 at 8:36 PM
prnewswire.com logoBioLineRx Reports First Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - May 25 at 5:01 PM
finance.yahoo.com logoBioLineRx Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 25 at 5:01 PM
finance.yahoo.com logoInvestor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call
finance.yahoo.com - May 25 at 5:01 PM
streetinsider.com logoBioLineRx (BLRX) Files BL-8040 Phase 1b Trial Regulatory Submission in Combo with atezolizumab in AML - StreetInsider.com
www.streetinsider.com - May 24 at 8:53 PM
finance.yahoo.com logoBioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML
finance.yahoo.com - May 22 at 11:40 AM
finance.yahoo.com logo[$$] BiolineRX Shares Could Triple
finance.yahoo.com - May 19 at 3:53 PM
americanbankingnews.com logoBioline RX Ltd (BLRX) Lifted to "Buy" at Maxim Group
www.americanbankingnews.com - May 18 at 8:34 AM
finance.yahoo.com logoBioLineRx to Report First Quarter 2017 Results on May 25, 2017
finance.yahoo.com - May 16 at 12:35 PM
streetinsider.com logoBioLineRx (BLRX) Initiate Phase 3 Study with BL-8040 Following Successful Meeting with FDA - StreetInsider.com
www.streetinsider.com - May 3 at 10:48 AM
finance.yahoo.com logoBioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
finance.yahoo.com - May 3 at 10:48 AM
americanbankingnews.com logoSomewhat Favorable Press Coverage Extremely Likely to Affect Bioline RX (BLRX) Share Price
www.americanbankingnews.com - April 28 at 9:48 AM
americanbankingnews.com logoShort Interest in Bioline RX Ltd (BLRX) Expands By 58.7%
www.americanbankingnews.com - April 26 at 11:50 PM
americanbankingnews.com logoBioline RX (BLRX) Given News Impact Score of 0.19
www.americanbankingnews.com - April 25 at 12:37 PM
americanbankingnews.com logoBioline RX Ltd (BLRX) PT Set at $4.00 by HC Wainwright
www.americanbankingnews.com - April 22 at 9:02 PM
americanbankingnews.com logoBioline RX Ltd (BLRX) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 21 at 8:28 PM
seekingalpha.com logoBiolineRx: COMBAT Engagement - Seeking Alpha
seekingalpha.com - April 20 at 4:03 PM
americanbankingnews.com logoBioline RX (BLRX) Getting Very Favorable Press Coverage, Report Finds
www.americanbankingnews.com - April 14 at 11:12 AM
finance.yahoo.com logoBioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares
finance.yahoo.com - April 7 at 8:33 AM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Bioline RX and Cara Therapeutics
finance.yahoo.com - April 3 at 4:21 PM
streetinsider.com logoBioLineRx (BLRX) to Offer ADSs - StreetInsider.com
www.streetinsider.com - March 31 at 9:04 PM
streetinsider.com logoBioLineRx (BLRX) Prices 29.4M Offering at $0.85/ADS - StreetInsider.com
www.streetinsider.com - March 31 at 9:04 PM
nasdaq.com logoMid-Day Market Update: Sorl Auto Parts Rises After Q4 Results; Bioline RX Shares Drop
www.nasdaq.com - March 31 at 4:04 PM
us.rd.yahoo.com logoBioLineRx Prices $25 Million Underwritten Public Offering
us.rd.yahoo.com - March 31 at 4:04 PM
finance.yahoo.com logoBioLineRx Announces Underwritten Public Offering of its American Depositary Shares
finance.yahoo.com - March 30 at 4:22 PM
finance.yahoo.com logoBIOLINERX LTD. Financials
finance.yahoo.com - March 28 at 6:07 PM
finance.yahoo.com logoBioLineRx's AGI-134 to be Presented at AACR 2017
finance.yahoo.com - March 27 at 11:40 AM
seekingalpha.com logoBioLineRx's (BLRX) CEO Philip Serlin on Q4 2016 Results ... - Seeking Alpha
seekingalpha.com - March 25 at 3:55 PM
streetinsider.com logoBioLineRx (BLRX) Acquires Agalimmune - StreetInsider.com - StreetInsider.com
www.streetinsider.com - March 24 at 3:19 PM
us.rd.yahoo.com logoBioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline
us.rd.yahoo.com - March 23 at 4:21 PM
finance.yahoo.com logoBioLineRx Reports Year End 2016 Financial Results
finance.yahoo.com - March 23 at 4:21 PM
americanbankingnews.com logoBioline RX Ltd (BLRX) PT Set at $1.00 by Maxim Group
www.americanbankingnews.com - March 21 at 3:39 PM
finance.yahoo.com logoBioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
finance.yahoo.com - March 20 at 11:29 AM
finance.yahoo.com logo7:01 am BioLineRx reports partial results data from its open-label Phase 2 trial for BL-8040 as a novel monotherapy approach for the mobilization and collection of blood forming stem and progenitor cells from the peripheral blood; top-line
finance.yahoo.com - March 20 at 11:29 AM
finance.yahoo.com logoBioLineRx to Report Annual 2016 Results on March 23, 2017
finance.yahoo.com - March 16 at 3:17 PM
finance.yahoo.com logoCoverage initiated on BioLineRx by Rodman & Renshaw
finance.yahoo.com - February 13 at 9:28 PM
finance.yahoo.com logoBioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14
finance.yahoo.com - February 7 at 4:55 PM
seekingalpha.com logoBioLine Rx: This Under-The-Radar Biotech Stock Is A Strong Buy At $1
seekingalpha.com - January 28 at 3:57 PM
finance.yahoo.com logoBioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda
finance.yahoo.com - January 19 at 3:37 PM
streetinsider.com logoBioLineRx (BLRX) Initiates Second Phase 2a Trial of BL-8040
www.streetinsider.com - January 18 at 2:44 AM
streetinsider.com logoBioLineRx (BLRX) Initiates Second Phase 2a Trial of BL-8040 - StreetInsider.com
www.streetinsider.com - January 17 at 4:41 PM
us.rd.yahoo.com logoBioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
us.rd.yahoo.com - January 17 at 9:33 AM
us.rd.yahoo.com logo7:59 am BioLineRx in slides details expected milestones in 2017/2018
us.rd.yahoo.com - January 9 at 5:02 PM
finance.yahoo.com logoBioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco
finance.yahoo.com - January 4 at 4:37 PM

Social

Chart

Bioline RX Ltd (BLRX) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff